

What Clinicians Want to Know About Anti-CD38 Antibodies in the Management of Multiple Myeloma

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. The Phase III MAIA trial demonstrated significant improvements in progression-free and overall survival with the addition of daratumumab to lenalidomide/dexamethasone for which subgroup of patients with multiple myeloma (MM)?**
 - Those with newly diagnosed, transplant-eligible disease
 - Those with newly diagnosed, transplant-ineligible disease
 - Those with previously treated, unfavorable-risk disease
- 2. Which of the following statements best describes outcomes observed in the Phase II GRIFFIN trial evaluating RVd/daratumumab for patients with newly diagnosed MM?**
 - Responses were best at the end of induction therapy
 - Responses were best at the end of autologous stem cell transplant
 - Responses were best at the end of consolidation therapy
 - The depth of responses improved over time
 - I'm not sure
- 3. The Phase III GMMG-HD7 trial evaluating the addition of isatuximab to RVd for transplant-eligible patients with MM demonstrated which of the following outcomes?**
 - A numerical but nonsignificant increase in undetectable minimal residual disease (uMRD) rates
 - A statistically significant increase in uMRD rates
 - Similar rates of uMRD in both study arms
- 4. Which patients were eligible for the Phase III ICARIA-MM study, which demonstrated a significant improvement in progression-free survival, with a 40% reduction in risk of progression or death, with the addition of isatuximab to pomalidomide/dexamethasone?**
 - Those with newly diagnosed disease
 - Those with relapsed disease after 1 prior line of therapy
 - Those with MM that relapsed after and/or was refractory to at least 2 lines of therapy, including lenalidomide and a proteasome inhibitor
- 5. A Phase Ib study for patients with relapsed/refractory MM is evaluating an on-body delivery system for subcutaneous administration of which agent in combination with pomalidomide/dexamethasone?**
 - Daratumumab
 - Isatuximab
 - Elotuzumab